In a column published Tuesday on PharmExec.Com, Precision Health Economics Senior Vice President and Head of Medical Affairs Ross Maclean and Precision Xtract Scientific Advisor Jeroen Jansen say the pharmaceutical industry should take a more active role in defining the value of their products.
They say they industry should change the widely-practiced strategy of only responding to evaluations conducted and reported by third-party entities rather than taking charge of the discussions.
“Given the decentralized decision-making environment in the U.S., cost-effectiveness analyses or any other analysis about value performed by different stakeholders have only relevance for decision-makers when there is total transparency and they have confidence in the analysis,” they write.
To read Maclean and Jansen’s full write up on PharmExec.Com, click here.
